SCHEMBL13135587

SCHEMBL13135587

c1cc2cc(C3=NCCN3)ccc2cc1C1=NCCN1

nearest known ligand 0.86

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 13/20 0.86
▸ PRMT1 Q99873 2/20 0.61
▸ LMNA P02545 1/20 0.58
▸ RECQL P46063 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5562588 0.98 NISCH (0.83) NISCHPRMT1LMNARECQL
Benazoline SCHEMBL9575180 0.93 NISCH (1.00) NISCHPRMT1
Benazoline SCHEMBL29349712 0.93 NISCH (1.00) NISCHPRMT1
SCHEMBL8195553 0.86 NISCH (0.87) NISCHLMNARECQL
SCHEMBL5476725 0.84 NISCH (0.79) NISCHLMNARECQL
SCHEMBL21335771 0.84 NISCH (0.63) NISCHPRMT1
SCHEMBL7735671 0.84 NISCH (0.74) NISCHPRMT1
SCHEMBL7738682 0.83 NISCH (0.63) NISCHPRMT1
SCHEMBL14865430 0.82 NISCH (0.79) NISCHPRMT1
SCHEMBL7735536 0.82 NISCH (0.60) NISCHPRMT1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697715-B2 Cucurbituril-based hydrogels SCHERMAN OREN (GB) 2023-07-11 — — US disclosed
US-20220411591-A1 CUCURBITURIL-BASED HYDROGELS SCHERMAN OREN (GB) 2022-12-29 — — US disclosed
EP-2736962-B1 SUPRAMOLECULAR CAPSULES CAMBRIDGE ENTPR LTD (GB) 2019-09-04 — — EP disclosed
US-20190263973-A1 CUCURBITURIL-BASED HYDROGELS LIU, Ji (GB) 2019-08-29 — — US disclosed
US-10189955-B2 Nested supramolecular capsules CAMBRIDGE ENTERPRISE LIMITED (GB) 2019-01-29 — — US disclosed
WO-2018069516-A1 CUCURBITURIL-BASED HYDROGELS CAMBRIDGE ENTERPRISE LIMITED (GB/GB) (GB) 2018-04-19 — — WO disclosed
US-20170211023-A1 SUPRAMOLECULAR CAPSULES AQDOT LTD (GB) 2017-07-27 — — US disclosed
US-20170028374-A1 SUPRAMOLECULAR CAPSULES CAMBRIDGE ENTERPRISE LIMITED (GB) 2017-02-02 — — US disclosed
US-9439868-B2 Supramolecular capsules CAMBRIDGE ENTERPRISE LIMITED (GB) 2016-09-13 — — US disclosed
EP-2222757-B1 SUPRAMOLECULAR HANDCUFFS IN POLYMERIC ARCHITECTURE CAMBRIDGE ENTPR LTD (GB) 2016-09-07 — — EP disclosed
US-20150368407-A1 NESTED SUPRAMOLECULAR CAPSULES CAMBRIDGE ENTERPRISE LIMITED (GB) 2015-12-24 — — US disclosed
US-20150110772-A1 CUCURBITURIL-BASED HYDROGELS CAMBRIDGE ENTERPRISE LIMITED (GB) 2015-04-23 — — US disclosed
US-20140170214-A1 SUPRAMOLECULAR CAPSULES CAMBRIDGE ENTERPRISE LIMITED (GB) 2014-06-19 — — US disclosed
US-20140113382-A1 PLASMONIC JUNCTIONS FOR SURFACE-ENHANCED SPECTROSCOPY CAMBRIDGE ENTERPRISE LIMITED (GB) 2014-04-24 — — US disclosed
US-8378059-B2 Supramolecular handcuffs in polymeric architecture CAMBRIDGE ENTERPRISE LTD. (GB) 2013-02-19 — — US disclosed
US-8378059-B2 Supramolecular handcuffs in polymeric architecture CAMBRIDGE ENTERPRISE LTD. (GB) 2013-02-19 — — US disclosed
WO-2012175900-A1 PLASMONIC JUNCTIONS FOR SURFACE-ENHANCED SPECTROSCOPY CAMBRIDGE ENTERPRISE LIMITED (GB) 2012-12-27 — — WO disclosed
US-20100247477-A1 SUPRAMOLECULAR HANDCUFFS IN POLYMERIC ARCHITECTURE CAMBRIDGE ENTERPRISE LIMITED (GB) 2010-09-30 — — US disclosed
US-20100247477-A1 SUPRAMOLECULAR HANDCUFFS IN POLYMERIC ARCHITECTURE CAMBRIDGE ENTERPRISE LIMITED (GB) 2010-09-30 — — US disclosed
WO-2009071899-A2 SUPRAMOLECULAR HANDCUFFS IN POLYMERIC ARCHITECTURE CAMBRIDGE ENTERPRISE LIMITED (GB) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100247477-A1 SUPRAMOLECULAR HANDCUFFS IN POLYMERIC ARCHITECTURE CCR8, BIRC8, CBX8 NISCH 3430/4885PRMT1 3500/4885LMNA 4182/4885
US-20140170214-A1 SUPRAMOLECULAR CAPSULES TBCB, NOD2, ICOSLG NISCH 502/4885PRMT1 3315/4885LMNA 4497/4885
US-20220411591-A1 CUCURBITURIL-BASED HYDROGELS SMARCA5, CMBL, MGLL NISCH 520/4885PRMT1 1901/4885LMNA 4736/4885
US-20150110772-A1 CUCURBITURIL-BASED HYDROGELS JAK1, SHH, NOD2 NISCH 1289/4885PRMT1 3230/4885LMNA 4848/4885
US-11697715-B2 Cucurbituril-based hydrogels SMARCA5, CMBL, MGLL NISCH 520/4885PRMT1 1901/4885LMNA 4736/4885
US-10189955-B2 Nested supramolecular capsules UBAP2L, UBE2L6, CTR9 NISCH 817/4885PRMT1 4100/4885LMNA 4372/4885
US-20170028374-A1 SUPRAMOLECULAR CAPSULES TBCB, NOD2, ICOSLG NISCH 502/4885PRMT1 3315/4885LMNA 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback